BioSyent to Present at the LD 500 Virtual Conference
25 August 2020 - 6:30AM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today
announced that it will be presenting at the LD 500 investor
conference on Thursday, September 3rd at 2:40 p.m. (ET). Mr.
René Goehrum, President and CEO of BioSyent, will be presenting to
a live virtual audience. Mr. Goehrum will also be available
to meet with investors on a one-on-one basis during the conference
on September 1st to 4th. These one-on-one meetings can be
requested by registered attendees through the online conference
portal: https://ld-micro-conference.events.issuerdirect.com/
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that
treat these patients by marketing its products through its
community, specialty/hospital and international business units.
As of the date of this press release, the
Company has 12,808,170 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone:
905-206-0013Web: www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to
risks and uncertainties that may cause actual results or outcomes
to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited
to, those associated with clinical trials, product development,
future revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2024 to May 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2023 to May 2024